| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KNTE | Common Stock | Purchase | $156K | +61K | +11.09% | $2.55 | 611K | Apr 28, 2023 | See footnotes | F1, F8 |
| transaction | KNTE | Common Stock | Purchase | $583K | +229K | +6.52% | $2.55 | 3.74M | Apr 28, 2023 | See footnotes | F2, F8 |
| transaction | KNTE | Common Stock | Purchase | $156K | +61K | +11.09% | $2.55 | 611K | Apr 28, 2023 | See footnotes | F3, F8 |
| transaction | KNTE | Common Stock | Purchase | $326K | +125K | +20.38% | $2.62 | 736K | May 1, 2023 | See footnotes | F1, F4, F8 |
| transaction | KNTE | Common Stock | Purchase | $1.22M | +467K | +12.5% | $2.62 | 4.2M | May 1, 2023 | See footnotes | F2, F4, F8 |
| transaction | KNTE | Common Stock | Purchase | $326K | +125K | +20.38% | $2.62 | 736K | May 1, 2023 | See footnotes | F3, F4, F8 |
| transaction | KNTE | Common Stock | Purchase | $157K | +58.8K | +8% | $2.67 | 794K | May 2, 2023 | See footnotes | F1, F5, F8 |
| transaction | KNTE | Common Stock | Purchase | $589K | +221K | +5.25% | $2.67 | 4.43M | May 2, 2023 | See footnotes | F2, F5, F8 |
| transaction | KNTE | Common Stock | Purchase | $157K | +58.8K | +8% | $2.67 | 794K | May 2, 2023 | See footnotes | F3, F5, F8 |
| holding | KNTE | Common Stock | 84.6K | Apr 28, 2023 | See footnotes | F6, F8 | |||||
| holding | KNTE | Common Stock | 450K | Apr 28, 2023 | See footnotes | F7, F8 |
| Id | Content |
|---|---|
| F1 | These securities are held of record by OrbiMed Asia Partners IV, L.P. ("OAP IV"). OrbiMed Asia GP IV, L.P. ("Asia GP") is the general partner of OAP IV and OrbiMed Advisors IV Limited ("Advisors IV") is the general partner of Asia GP. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV. |
| F2 | These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII. |
| F3 | These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII. |
| F4 | Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.59 to a high of $2.64 per share. The Reporting Persons undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F5 | Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.57 to a high of $2.82 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F6 | These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis. |
| F7 | These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM. |
| F8 | Each of the Reporting Person, OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |